422 related articles for article (PubMed ID: 9329573)
1. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
2. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
[TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
4. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Cramer C; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2903-6. PubMed ID: 9329559
[TBL] [Abstract][Full Text] [Related]
6. The serum tumor marker M3/M21 in the follow-up of breast cancer patients.
Tempfer C; Hanzal E; Zeillinger R; Koelbl H; Dadak C; Kainz C
Anticancer Res; 1996; 16(5B):3049-52. PubMed ID: 8920765
[TBL] [Abstract][Full Text] [Related]
7. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of four serological tumor markers for the detection of breast cancer.
Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
[TBL] [Abstract][Full Text] [Related]
11. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
Hu XC; Day W; Jones B; Loo WT; Chow LW
Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
[TBL] [Abstract][Full Text] [Related]
13. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
Fritsche E; Benz J
Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors.
Lumachi F; Brandes AA; Ermani M; Bruno G; Boccagni P
Anticancer Res; 2000; 20(6C):4751-5. PubMed ID: 11205212
[TBL] [Abstract][Full Text] [Related]
15. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
16. [Tumor markers in the diagnosis and prognosis of breast cancer].
Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
[TBL] [Abstract][Full Text] [Related]
17. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
Eskelinen M; Tikanoja S; Brown J
Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]